**NSW TAG ACTIVITIES**

**Upcoming TAG Meetings**
- TAG Management Committee meeting: 8.30-10am 17th February
- TAG General Member meeting- 17th February 10am-12 noon

- Information primer: [Cannabis Medicines Use in Hospitals](#) updated 4/2/21 to reflect scheduling changes.

**New open email discussions**
- Anaesthetic failures with bupivacaine, closes 15/02/2021

**Recently completed email discussions**
- Oral paediatric phenobarbitone & diazepam products
- Availability of medical grade freezers and storage of Cervagem

**COVID-19**
Visit the NSW TAG COVID-19 [webpage](#) for links to latest updates and a summary of activities including a summary of clinical trials in NSW and other jurisdictions.

*NSW Health Drug & Therapeutics Advisory Community of Practice (DaTA CoP) for COVID-19.*
(See other key clinical specialties [communities of practice](#)).
- Next meeting Wed 9am 3 March 2021. Guest speaker: A/Prof Vivien Chen, Clinical Haematologist, Concord Hospital, Anticoagulants in COVID-19
- Co-chairs: Prof Sarah Hilmer & Ms Jenny Crane. If you would like to join the CoP email [NSW TAG](#)
- DaTA CoP SharePoint site includes a list of COVID-19-related enquiries to NSW Medicines Information Pharmacists.

**COVID-19 RESOURCES & ARTICLES OF INTEREST**
Please click this [link](#) for the cumulative listing of COVID-19 resources in past TAG Mails.

### AUSTRALIAN

**Australian Government Department of Health**
- Australian Health Protection Principal Committee (AHPPC) updated statement on minimising the potential risk of COVID-19 transmission in schools - [link](#)
- Australia’s vaccination strategy - [link](#)
- Minimising the risk of infectious respiratory disease transmission in the context of COVID-19: the hierarchy of controls - [link](#)
- COVID-19 National Incident Room Surveillance Team:
  -- Epidemiology Report 34 - reporting period [ending 31 January 2021](#); technical [supplement](#)

**Australasian Society of Clinical Immunology and Allergy (ASCIA)**
- Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination Position Statement - [link](#), [FAQ](#)
- [link](#)

**NSW Health Critical Intelligence Unit**
- Emerging evidence about COVID-19 vaccines evidence check (update 5/2/21) - [link](#)
- SARS-CoV-2 variants evidence check (update 5/2/21) - [link](#)
- Self-collected and saliva test evidence check 8/2/21 - [link](#)
- 10 Feb 2021 - Risk Monitoring [Dashboard](#)

**Royal Australian College of General Practitioners**
- COVID-19 vaccine information for GPs - [link](#)
Society of Hospital Pharmacists of Australia (SHPA)
- Webinar: Global challenges with COVID-19 vaccines - 7pm AEDT, Thurs 25 February - [link]

TGA
- COVID-19 vaccine safety monitoring and reporting - [link]

INTERNATIONAL
Organisation for Economic Co-operation and Development (OECD)
- Policy Responses to Coronavirus (COVID-19) vaccines for developing countries: An equal shot at recovery - [link]

WHO
- Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2: scientific brief, 8 February 2021 - [link]
- Community needs, perceptions and demand: community assessment tool: a module from the suite of health service capacity assessments in the context of the COVID-19 pandemic: interim guidance, 5 February 2021 - [link]
- Operational guidance: legal and regulatory framework facilitating vaccine deployment - [link]
- Different types of COVID-19 vaccines - [link]
- WHO launches pilot social listening tool for COVID-19 - platform analyses people’s questions and concerns in 20 countries to help ensure they receive accurate and understandable health information
- Online vaccination training for health workers - free 3-hour course to ensure safe and efficient COVID-19 vaccine administration - [link]
- Data for action: achieving high uptake of COVID-19 vaccines: gathering and using data on the behavioural and social drivers of vaccination: a guidebook for immunization programmes and implementing partners: interim guidance, 3 February 2021 - [link]
- Acceptance and demand for COVID-19 vaccines 31 January 2021: interim guidance; communications plan template,
- 10 steps to community readiness: what countries should do to prepare communities for a COVID-19 vaccine, treatment or new test, 8 February 2021 - [link]
- Conducting community engagement for COVID-19 vaccines: interim guidance, 31 January 2021

Canada
Health Canada – MedEffect Notice
- Pfizer-BioNTech COVID-19 Vaccine: Updated Dosage and Administration and Post-Market Adverse Reaction Information - [link]

Europe
EMA
- EMA reviewing data on monoclonal antibody use for COVID-19 - [link]
- EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373) - [link]

UK
- Department of Health and Social Care
-- World-first COVID-19 alternating dose vaccine study launches in UK - [link]
-- Suitability for COVID-19 vaccination based on prior allergy or current dietary practices - [link]
-- Latest monitoring data confirms safety of COVID-19 vaccines - [link]
-- Report: Coronavirus (COVID-19) vaccine adverse reactions - [link]
-- Interleukin-6 inhibitors (tocilizumab and sarilumab) for critically ill patients with COVID-19 pneumonia (adults) - [link]
-- COVID-19 vaccination programme: Information for healthcare practitioners (updated) - [link]
-- Scottish Intercollegiate Guideline Network (SIGN) UK
-- Evidence Review: Assessment of COVID-19 in primary care: the identification of symptoms, signs, characteristics, comorbidities and clinical signs in adults, children and young people, which may indicate a higher risk of progression to severe disease - [link]
Specialist Pharmacy Services NHS UK
-- Summary of COVID-19 medicines guidance (updated): Respiratory disorders

The Kings Fund
-- Covid-19 recovery and resilience: what can health and care learn from other disasters? - link
-- Resources: Leading through Covid-19: supporting health & care leaders in unprecedented times

USA
-- American Society of Health-System Pharmacists (ASHP)
  -- ASHP discussion forum (Sign up for free) recent topics of discussion include: sharing of different suspect vaccines ADR; vaccination cards;
  -- Optimizing the Preparation and Administration of COVID-19 Vaccines (2/4/2021) – link
  -- Centers for Disease Control and Prevention (CDC)
  -- Decline in COVID-19 Hospitalization Growth Rates Associated with Statewide Mask Mandates - 10 States, March-October 2020 - link
  -- Demographic Characteristics of Persons Vaccinated during the First Month of the COVID-19 Vaccination Program - United States, December 14, 2020-January 14, 2021 - link
  -- Toolkit for Pregnant People and New Parents - link
  -- COVID-19 Frequently Asked Questions (updated) - link
  -- COVID-19 Vaccine Information for Specific Groups - link
-- FDA
  -- FDA alerts health care professionals and compounders of potential risks associated with the compounding of remdesivir drug products - link
  -- FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma to Reflect New Data - link
  -- Emergency use authorization (EUA) issued for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients
-- ISMP
  - COVID-19 Medication Safety Resource Page - link
-- The Joint Commission
  -- Quick Safety 57: Supporting safe, equitable care during the COVID-19 pandemic - link

JOURNAL ARTICLES
American Journal of Health-System Pharmacy (AJHP)
- Antimicrobial stewardship perspectives from a New York City hospital during the COVID-19 pandemic: Challenges and opportunities - link
- Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States - link

Annals of Internal Medicine
- Major Update: Remdesivir for Adults with COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points - link

BMJ
- Why aren’t covid-19 vaccines being manufactured in standard prefilled syringes? - link
- Analysis: Put to the test: use of rapid testing technologies for covid-19 - link

Emerging Infectious Diseases
- COVID-19–Associated Pulmonary Aspergillosis, March–August 2020 - link

Environmental Research
- Evaluation of SARS-COV-2 transmission through indoor air in hospitals and prevention methods: A systematic review - link

European Journal of Clinical Pharmacology
- The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials - link

Health Affairs
- Variation In Telemedicine Use And Outpatient Care During The COVID-19 Pandemic In The United States - link
Infection Control & Hospital Epidemiology
- Air contamination of households versus hospital inpatient rooms occupied by SARS-CoV-2 positive patients - link

International Journal of Infectious Diseases
- Incubation period of COVID-19: a meta-analysis - link

JAMA
- Viewpoint: A Viral Pandemic, Vaccine Safety, and Compensation for Adverse Events - link
- Viewpoint: COVID-19 Vaccination in Pregnant and Lactating Women - link
- Research letter: Comparison of Demand for Drugs Used for COVID-19 Treatment and Other Drugs during the Early Phase of the COVID-19 Pandemic in Italy - link
- Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated with COVID-19 Infection among Outpatients in Virginia - link
- Susceptibility to SARS-CoV-2 Infection among Children and Adolescents Compared With Adults - link
- Research letter: Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients with COVID-19. A Randomized Clinical Trial - link

JAMA Health Forum
- Experts Offer Advice to Shore Up Confidence in COVID-19 Vaccines - link

Lancet
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - link
- Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial - link
- Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study - link
- Report: Understanding variants of SARS-CoV-2 - link
- COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics - link
- Correspondence: CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants - link

Nature Communications
- Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers - link

Nature Podcast
- Coronapod: Variants – what you need to know - link

New England Journal of Medicine
- Covid-19 Vaccine Training: Explore the virology of SARS-CoV-2, mechanism of action of Covid-19 vaccines, the efficacy and safety of currently available Covid-19 vaccines, and the practicalities involved in vaccine administration – Free online course - link
- Commentary: Opportunities for Artificial Intelligence–Enabled Social Media Analysis of Public Attitudes toward Covid-19 Vaccines - link
- Comment: SARS-CoV-2 vaccination and phase 1 cancer clinical trials - link

medRxiv
- Pre-print: Decreased SARS-CoV-2 viral load following vaccination - link
- Pre-print: Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals - link

Postgraduate Medical Journal
- Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis - [link](#)

PROSPERO - International prospective register of systematic reviews
- The use of janus kinase inhibitors in hospitalized patients with COVID-19: systematic review and meta-analysis - [link](#)

Thorax
- Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people - [link](#)

---

**OTHER NEWS (bold = new)**

**Research Surveys**
- Tele-PC Study: examining consumer and clinician perspectives on the use of telehealth for cardiovascular care in Australia – survey [link](#) closes on 16 February 2021

**Australian Digital Health Agency**
- Digital Health Specialist Toolkit - A new resource is available to assist private specialist practices to better understand and adopt digital health technologies - [link](#)

**Australian and New Zealand College of Anaesthetists (ANZCA), Faculty of Pain Medicine (FPM)**
- Pain management education strategy project update - [link](#)

**Australian Healthcare and Hospitals Association (AHHA)**
- Palliative Care Training - New and improved – see [portal](#)

**Australian Prescriber**
- New drugs: [Sellexipag](#) for pulmonary arterial hypertension

**Drug & Alcohol Specialist Advisory Service managed by St Vincent’s Hospital Alcohol and Drug Service in Sydney**
- Free 24/7 telephone service that provides general advice to health professionals who require assistance with the clinical diagnosis and management of patients with alcohol and other drug related concerns. Within Sydney Metropolitan Area: (02) 8382-1006; Regional, Rural & Remote NSW: 1800 023 687; [website](#)

**Drug and Alcohol Services South Australia**
- Alcohol and drug stigma resources including videos - [link](#)

**NPS MedicineWise**
- Active ingredient prescribing: [information hub](#) & Factsheets for [primary care prescribers](#); [pharmacists](#); [consumers](#)

**NSW Health**
- Senior Pharmaceutical Officer - Regulatory Policy - vacancy for a part-time job-share role, 2 days per week, in the Chief Pharmacist Unit in the Ministry of Health, closes 16/02/2021 - [link](#)

**PBS**
- Active Ingredient Prescribing [webpage](#), Pharmacist [FAQS](#)

**WHO**
- WHO issues new 10-year plan to end suffering from neglected tropical diseases - [link](#)

---

**REPORTS AND PUBLICATIONS – AUSTRALIA**

**AHHA**
- Evidence Brief No. 22 - Supporting school aged children with Developmental Language Disorder (DLD) - [link](https://example.com)

**Australian Commission on Safety and Quality in Health Care (ACSQHC)**
- Active Ingredient Prescribing - [link](https://example.com), fact sheet [link](https://example.com), prescriber user guide [link](https://example.com)
- List of Medicines for Brand Consideration (LMBC) – [link](https://example.com)
- List of Excluded Medicinal Items (LEMI) - [link](https://example.com)

**Australian Institute for Health and Welfare (AIHW)**
- Eye health - [link](https://example.com)

**TGA**
- AusPARs
  -- [Decitabine and cedazuridine](https://example.com) (Inqovi 35/100) is indicated for the treatment of adult ps with myelodysplastic syndromes (MDS) intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups, and patients with chronic myelomonocytic leukaemia (CMML)
  - Registration of [new or extended uses](https://example.com) of registered medicine
  -- Tremfya (guselkumab) for treatment of adult patients with active psoriatic arthritis, who have had an inadequate response to, or are intolerant to prior DMARD therapy.

### REPORTS AND PUBLICATIONS – INTERNATIONAL

**Agency for Healthcare Research and Quality (AHRQ) USA**
- Research Protocol: Management of Infantile Epilepsy - [link](https://example.com)

**Canadian Agency for Drugs and Technologies in Health**
- Rapid Response: Hypertonic Saline for the Treatment of Diabetic Ketoacidosis in Children - [link](https://example.com)

**Care Quality Commission (UK)**
- Enabling innovation and adoption in health and social care: Developing a shared view - [link](https://example.com)

**electronic Medicines Compendium (UK)**
- Licence extensions
  -- Nplate ([romiplostim](https://example.com)) for chronic primary immune thrombocytopenia in paediatric patients’ ≥ 1 year of age refractory to other treatments (e.g. corticosteroids, immunoglobulins)
  -- Tivicay ([dolutegravir](https://example.com)) - paediatric extension. Use in combination with other antiretrovirals, for HIV in children from 6 years old, weighing at least 14kg. New dispersible tablets for children aged ≥ 4 weeks and weighing ≥ 3 kg now available. Elevated bilirubin levels added as rare side-effect.
  -- Doptelet ([avatrombopag maleate](https://example.com)) - for primary chronic immune thrombocytopenia in adults who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

**European Medicines Agency (EMA)**
- Nitrosamine impurities - [link](https://example.com)

**Food and Drug Administration (FDA) USA**
- New Drug approvals
  -- Breyanzi ([lisocabtagene maraleucel](https://example.com)) - for adults with relapsed or refractory Large-B-Cell Lymphoma
  -- Tepmetko ([tepotinib](https://example.com)) – for non-small cell lung cancer
  -- Ukoniq ([umbralisib](https://example.com)) – for relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma

**NHS England**
- Managing a healthy weight in adult secure services – practice guidance - [link](https://example.com)

**National Institute for Health and Clinical Excellence (NICE) UK**
- Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
- Leukomed Sorbact for preventing surgical site infection (MTG55)
MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)
- Revised SPCs
  -- Indivina (medroxyprogesterone acetate/estradiol valerate) – Large meta-analysis showed that after stopping treatment, excess risk of breast cancer will decrease with time and time needed to return to baseline depends on duration of prior HRT use.
  -- Salofalk (mesalazine) - Stevens-Johnson syndrome and toxic epidermal necrolysis added as adverse effects (unknown frequency).
  -- Triumeq (lamivudine/abacavir sulfate/dolutegravir sodium) 50 mg/600 mg/300 mg film-coated tablets - In vitro study found concomitant administration of single dose riociguat (0.5 mg) led to 3-fold higher riociguat levels. Elevated bilirubin levels added as a rare adverse effect.
  -- Enbrel (etanercept) - Headache added as an ADR (very common frequency).
  -- Ozempic (semaglutide) - updated to incorporate information from a study of semaglutide as add-on to SGLT2 inhibitor treatment (SUSTAIN 9), including efficacy results and safety (rates of hypoglycaemia and gastrointestinal adverse events).
  -- Rydapt (midostaurin) – do not use in combination with intensive paediatric AML combination chemotherapy regimens including anthracyclines, fludarabine and cytarabine because of risk of prolonged haematological recovery (e.g. prolonged severe neutropenia and thrombocytopenia).
  -- Lamotrigine – added information on photosensitivity reactions. In several cases, the reaction occurred with a high dose (≥ 400mg), upon dose escalation or rapid up-titration.
  -- Sertraline -updated to include information on the risk of developing Serotonin Syndrome or Neuroleptic Malignant Syndrome, including increased risk with concomitant use of other serotonergic medicines.
  -- Duloxetine -updated to include caution in the elderly, risk of serotonin syndrome when using concomitantly with serotonergic agents. Also details new potential adverse effect of postpartum haemorrhage (unknown frequency)
  -- Venlafaxine - a new potential adverse effect of postpartum haemorrhage (unknown frequency).

EMA
- Sorafenib product-specific bioequivalence guidance (update) - link

Food and Drug Administration (FDA) USA
- Tofacitinib (Xeljanz, Xeljanz XR):
  -- Initial safety trial results find increased risk of serious heart-related problems and cancer - link
  -- FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib - link
  -- Product Information (Labelling) safety-related changes:
  -- Lamotrigine –Updated warnings and precautions – In vitro testing showed that lamotrigine exhibits Class IB antiarrhythmic activity at therapeutically relevant concentration. Lamotrigine could slow ventricular conduction (widen QRS) and induce proarrhythmia, including sudden death, in patients with structural heart disease or myocardial ischemia. Recommend avoiding use in patients with cardiac conduction disorders (e.g., second- or third-degree heart block), ventricular arrhythmias, or cardiac disease or abnormality (e.g., myocardial ischemia, heart failure, structural heart disease, Brugada syndrome or other sodium channelopathies). Concomitant use of other sodium channel blockers may increase the risk of proarrhythmia - link; ILAE/AES Task Force Advisory document - link

Institute for Safe Medication Practices (ISMP) USA
- ISMP Identifies Errors with Extended-Release Opioids, Infusion Pumps as among Top Medication Safety Issues in 2020 - link
  -- Updated Guidance Needed for Longstanding Large Volume Parenteral (LVP) Labeling and Packaging Problems
  -- Cisatracurium mislabeling incident calls for more efficient ways to alert the field
  -- Dosing errors with ENTRESTO
  -- Syringe with trailing zeros

TGA
- Safety information: Resurrection Male Sexual Enhancement capsules pose a serious risk to your health and should not be taken - link
PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)
- Iodine allergy: Common misperceptions - link
- Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection - link
- Drug information: Atoltivimab, Maftivimab, and Odesivim-ebgn - link
- The high-value pharmacy enterprise framework: Advancing pharmacy practice in health systems through a consensus-based, strategic approach - link
- Assessment of the impact of an opioid-specific education series on rates of medication-assisted treatment for opioid use disorder in veterans - link
- Brief intervention medication therapy management: Establishment of an opioid misuse intervention model delivered in a community pharmacy - link
- The substance use intervention team: A hospital-based intervention and outpatient clinic to improve care for patients with substance use disorders - link
- Point-of-care naloxone distribution in the emergency department: A pilot study - link

Annals of Internal Medicine
- Acute Pancreatitis - link
- Should You Recommend Cannabinoids for This Patient With Painful Neuropathy? Grand Rounds Discussion From Beth Israel Deaconess Medical Center - link

Arthritis & Rheumatology
- Review: New Therapeutic Targets in Antineutrophil Cytoplasm Antibody–Associated Vasculitis - link
- Long-Term Outcomes in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries - link
- ACR, AAD, RDS, and AAO 2020 Joint Statement on Hydroxychloroquine Use with Respect to Retinal Toxicity - link
- Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial - link

Australian Health Review, Journal of the Australian Healthcare & Hospitals Association
- Developing and piloting an adaptable oxycodone quality improvement strategy: steps towards opioid stewardship - link

British Journal of Clinical Pharmacology
- Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study - link
- Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial - link
- Impact Of Antiocoagulant Exposure Misclassification On The Bleeding Risk Of DOACs - link
- A pharmacovigilance study of pharmacokinetic drug interactions using a translational informatics discovery approach - link
- Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and pediatric populations - link

British Journal of Psychiatry
- Effectiveness of exercise-based interventions in reducing depressive symptoms in people without clinical depression: systematic review and meta-analysis of randomised controlled trials - link

BMC Health Services Research
- Delivering exceptionally safe transitions of care to older people: a qualitative study of multidisciplinary staff perspectives - link
- Acting between guidelines and reality- an interview study exploring the strategies of first line managers in patient safety work - link

British Medical Journal (BMJ)
- Clinical Review: Uveitis for the non-ophthalmologist - link
- Absolute cardiovascular disease risk score and pharmacotherapy at the time of admission in patients presenting with acute coronary syndrome due to coronary artery disease in a single Australian tertiary centre: a cross-sectional study - link
- Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study

BMJ DTB
- Republished: Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency - link

BMJ Quality and Safety
- Adherence to guideline-recommended HbA1c testing frequency and better outcomes in patients with type 2 diabetes: a 5-year retrospective cohort study in Australian general practice - link

Circulation
- Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMeplagilf lozin Evaluation By MeasuRing ImpAct on HemodyNamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial - link
- Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial - link
- Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial - link

Cochrane
- Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer - link
- Salbutamol for transient tachypnea of the newborn - link
- Skin care interventions in infants for preventing eczema and food allergy - link
- Brexipiprazole versus placebo or other antidepressive agents for treating depression - link
- Ozanimod for relapsing-remitting multiple sclerosis - link

Diabetes Care
- Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People with Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study - link
- Rapid Changes in Serum Testosterone in Men with Newly Diagnosed Type 2 Diabetes with Intensive Insulin and Metformin - link

European Journal of Hospital Pharmacy
- Case Report: An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage - link

Health Expectations
- How different health literacy dimensions influences health and well-being among men and women: The mediating role of health behaviours - link
- Knowledge sharing to support long-term condition self-management—Patient and health-care professional perspectives - link

Health Technology Assessment
- Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation - link

Internal Medicine Journal
- Patterns of azithromycin use in obstructive airway diseases: a real-world observational study - link

International Journal of Clinical Pharmacy
- Potentially inappropriate prescriptions and therapeutic complexity in older HIV patients with comorbidities - link
- Impact of clinical pharmacist services on quality adjusted life years in head and neck cancer patients - link

International Journal for Quality in Health Care
- Time and Predictors of Treatment for Aneurysmal Subarachnoid Haemorrhage (ASAH): A Systematic Review - link
- Mitigating Imperfect Data Validity in Administrative Data PSIs: a Method for Estimating True Adverse Event Rates - [link]

JAMA
- Review: Diagnosis and Treatment of Hip and Knee Osteoarthritis - [link]

JAMA Internal Medicine
- Risk of Progression to Diabetes among Older Adults with Prediabetes - [link]
- Teachable moment: The Toxic Effects of an Incomplete Medication History - [link]

JAMA Network Open
- Association of Rituximab Use with Adverse Events in Children, Adolescents, and Young Adults - [link]
- Comparison between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism - [link]
- Association between Statin use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction - [link]

JAMA Neurology
- Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis. A Randomized Clinical Trial - [link]

JAMA Oncology
- Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men. Results from the MALE Phase 2 Randomized Clinical Trial - [link]

JAMA Pediatrics
- Association between Proton Pump Inhibitor use and risk of Asthma in Children - [link]

JAMA Surgery
- Early Corticosteroid Cessation vs Long-term Corticosteroid Therapy in Kidney Transplant Recipients. Long-term Outcomes of a Randomized Clinical Trial - [link]

JAMIA (Journal of the American Medical Informatics Association)
- Advancement in predicting interactions between drugs used to treat psoriasis and its comorbidities by integrating molecular and clinical resources - [link]
- Moving toward a sociotechnical systems approach to continuous health information technology design: the path forward for improving electronic health record usability and reducing clinician burnout - [link]

Journal of Clinical Oncology
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up - [link]

Journal of Patient Safety
- The Association between Health Care Staff Engagement and Patient Safety Outcomes. A Systematic Review and Meta-Analysis - [link]

Journal of Palliative Medicine
- An Assessment of Emergency Department-Based Interventions for Patients with Advanced or End-Stage Illness: A Systematic Review - [link]

Journal of Pharmacy Practice and Research (JPPR)
- Interventions to decrease the incidence of dispensing errors in hospital pharmacy: a systematic review and meta-analysis - [link]
- Review: Pharmacological management of stroke in older people - [link]
- Review: Carbamazepine, oxcarbazepine, and lacosamide as adjunctive analgesics: a review of the literature - [link]

Lancet
- Review: Established and novel therapeutic options for autoimmune hepatitis - [link]
- Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial - link

**Molecular Diversity Preservation International (MDPI) – Pharmacy Journal**
- Pharmaceutical Discharge Management: Implementation in Swiss Hospitals Compared to International Guidelines - link
- Application of Standardized Antimicrobial Administration Ratio as a Motivational Tool within a Multi-Hospital Healthcare System - link
- What Is Known about Community Pharmacy-Based Take-Home Naloxone Programs and Program Interventions? A Scoping Review - link
- The Association between Medication Experiences and Beliefs and Low Medication Adherence in Patients with Chronic Disease from Two Different Societies: The USA and the Sultanate of Oman - link

**Medical Journal of Australia**
- High prevalence of Crohn disease and ulcerative colitis among older people in Sydney - link
- Research Letter: Residential medication management reviews in Australian residential aged care facilities - link

**National Institute for Health Research (NIHR) Signals**
- Active monitoring in early prostate cancer prevents as many deaths as surgery or radiotherapy, new research shows - link
- A simple checklist reliably identified paranoia in adolescents with mental health problems, research shows - link

**New England Journal of Medicine**
- Review: Management of Antithrombotic Therapy after Acute Coronary Syndromes - link

**Pediatrics**
- Improving Influenza Vaccination in Children with Comorbidities: A Systematic Review - link
- Marijuana Use to Address Symptoms and Side Effects by Youth with Chronic Medical Conditions - link

**Pediatric Anesthesia**
- Outcomes from wake up safe, the pediatric anesthesia quality improvement initiative - link

**Pharmacotherapy**
- Factors Influencing Antibiotic Duration in Culture-Negative Neonatal Early-Onset Sepsis - link
- Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab - link
- Association between the timing of asthma diagnosis and medication use during pregnancy - link
- Comparative Effectiveness and Safety of High-Dose Rivaroxaban and Apixaban for Atrial Fibrillation: A Propensity Score-Matched Cohort Study - link
- Influence of Digoxin on Mortality in Patients with Atrial Fibrillation: Overview of Systematic Reviews - link

**CONSULTATIONS (new additions in bold)**

**Australian Commission on Safety and Quality in Health Care (ACSQHC)**
- Draft Credentialing and Defining Scope of Clinical Practice guide, closes Friday 30 April 2021 - link

**WEBINARS & PODCASTS**

**Australian Rheumatology Association**
- Webinar: Opioids and Inflammatory Arthritis – the Current State of Evidence and Use in Australia What you really need to know. Wednesday 17 February 2021 at 8pm AEST - link

**Australian Commission on Safety and Quality in Health Care**
- Better Care Everywhere, Healthcare Variation in Practice online program series. Starting in February 2021. Click below to find out more about each webinar and to register
  11 February Preventing a problem: Opioid prescribing in hospitals
  16 February Vanishing variation: Practical tips for doing more of the same
  23 February NSQHS Standards action 1.28: Your roadmap to better care

Health Education and Training (HETI)
- Webinar: Publishing your Research – Publish or Perish? Wed 3 March 2021, 6-7pm (AEDT)

ISMP
- Call to Action: Experience in Adopting the ENFit System to Guard Against Accidental Tubing Misconnections, Feb 25, 2021 05:00 AM AEDT - link

NEJM Catalyst Innovations in Care Delivery
Health Care 2030, Free Virtual Event Series
- Health Systems in 2030, March 04, 2021, 4:00 am - 6:00 am AEDT - register
- Patients & Consumers in 2030, June 10, 2021 – more info here
- Technology & Data in 2030, September 09, 2021 – more info here
- Clinicians in 2030, December 09, 2021 – more info here

UPCOMING EVENTS
(New additions listed in TAGMail - click here for the running list of other events)
Nil new added

The purpose of TAG Mail is to assist TAG members to identify and share relevant information for their professional practice. Members are encouraged to routinely forward TAG Mail to others who they believe would benefit from this information such as colleagues in the same hospital department. TAG Mail as a standing agenda item in clinical pharmacists’ and other clinicians’ meetings may help facilitate discussion of contemporary and emerging medicines and practice.

You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy Policy. Please contact NSW TAG at nswtag@stvincents.com.au if you have any questions regarding this. Click here if you are not already subscribed to automatically receive this newsletter in your inbox and would like to